Customer Reviews

New Cancer Therapies: The Patient's Dilemma (Your Personal Health)

5 star:		(1)
4 star:		(1)
3 star:		(0)
2 star:		(0)
1 star:		(0)

 

 

Even with the best intentions, doctors and organizations like the American Cancer Society cannot evaluate new therapies for cancer objectively or thoroughly. Every branch of my family has gotten some form of swiftly killing cancer. The half that took the "traditional" forms with chemo and radiation all died within a few years, at max. The other half has lived and still live, in some cases 20+ years later! Their cancer therapy is listed as a "quackery" on ACS's site and no doctor supported them in their choice! Mainstream medicine doesn't have the wherewithall to correct its own misjudgements. So, don't take anyone's work for granted and explore the possibilities thoroughly before choosing.

This book outlines a number of choices in a fashion that allows you, who know your body the best of *anybody*, to choose what's right for you!

You have got to understand that doctors are under the penalty of loosing their livelihood if they fall out of the norm. Patients can die right and left, if the therapy is traditional, normal, and expected. Not a single patient can die if the therapy is different. No, it's not fair, but it's the direct result of our litigious society. It's no one's fault, but it's your life, so don't give it up to cancer or chemo!

In 1998, Health Canada approved Xeloda in the treatment of advanced breast cancer. The approval was based on a clinical trial of 162 women across Canada. The trial found that one in five had a 50 percent or greater reduction in their tumors. 20 percent was enough to gain regulator approval suggesting a 80 percent failure rate. In the trial the drug did not extend the patients lives.

IDM Pharma lead product mifamurtide, is a family of macrophage activators. The macrophage activators is a L-MTP-PE activates macrophages in the body to kill cancer cells.

Dendreon is creating a new class of cancer therapy known as Active Cellular Immunotherapies. ACI goal is to turn the immune system against cancer.